new treatments
for cancer - now!

About Us



Alan Walker MSc BSc (Psych) BSc (Biol) ACCA diploma in Accounting & Finance, Chartered Director.

Alan has been working for 46 years in the pharmaceutical industry. Positions held include Director international marketing and later, Director corporate strategic planning Warner Lambert NJ USA, General Manager Warner Lambert Belgium/ Luxembourg. Regional President pharmaceuticals Warner Lambert UK and Scandinavia (being first affiliate to launch Neurontin (gabapentin) and Lipitor (atorvastatin) in the world). Managing Director Elan UK JV. Regional President Warner Lambert Italy / Greece. Member Warner Lambert EU Board. Vice President Global Operations ProStrakan. Joint (sales and marketing) CEO Internis Pharmaceuticals, founded 2010 – highly profitable exit 2014.  Now CEO Ryboquin, managing the virtual team of scientists towards developing a major new oncology product.

Ex Vice President Association British Pharmaceutical Industry (ABPI). Freeman & Liveryman City of London, Fellow Institute of Medicine, Fellow Institute of Directors, Fellow Institute of Marketing, Fellow Royal Society of Arts. Registered psychometric analyst. Final year PhD student Dundee University. Ocean Yachtmaster.

Focussed on getting results through teamwork at sea, business and research. Believes in the value of excellence through group performance. Sees his role as providing that opportunity. Alan has demonstrated a business history of outstanding team results in all the above companies.



Paul’s a chartered accountant with over 25 years experience in the private equity market having been a director of 3i plc and a partner in Deutsche Bank’s private equity business. Paul now runs his own private equity fund.



Dr David Harrison is a medical doctor and Director of Laboratory Medicine for Edinburgh hospitals, incorporating pathology, microbiology, genetics, haematology and clinical biochemistry. For 13 years he was also Professor of Pathology in the University of Edinburgh, where he still holds an honorary chair.  His main interests are in pathology, systems medicine and cancer biomarkers and treatment. He established the Edinburgh Experimental Cancer Medicine Centre in 2007, with grant support from Cancer Research UK. He has published extensively in cancer and cell death. He chairs the Steering Group of the EU funded programme CASyM, concerted action for implementation of systems medicine across Europe.



Prof Alistair Strachan received his PhD in Biochemistry from the University of Strathclyde, Glasgow and his MBA from the University of Stellenbosch Graduate School Of Business, Cape Town. He has nearly 20 years’ experience in corporate pharma, spanning the generic and research-based industries, in South Africa, the US and the UK having held senior executive positions at the South African Druggists Group (COO of US subsidiary Capricorn Pharma Inc.), GlaxoSmithKline (Head of Operations Neurology & GI Centre of Excellence for Drug Discovery), Wyeth (Head of Operations for the US based global Discovery organization & VP and Head of Licensing and Business Development EMEA region) and Pfizer. Most recently, Alistair has been Head of Operations Global Biotherapeutics Technologies, Pfizer and site head of their Aberdeen, UK R&D operation. He is currently serving as Interim Chairman for Fios Genomics. In addition, Alistair has served on the Country Coordinating Council of the Pfizer UK Board and on the Life Sciences Industry Advisory Board of the Scottish Government. In July 2012 he was made an Honorary Professor by the University of Aberdeen.



Matthew graduated from Oxford University in 1988. Following a spell at Morgan Stanley International focusing on equity and equity derivative products, he established a consultancy business assisting large corporates investigating start-up opportunities, mainly in the healthcare field.  In 1997, he joined Rettie & Co, a leading Edinburgh-based property agent, where he has overseen the expansion in Land and Development, New Homes and Research and Consultancy departments. More recently he has been working closely with the Scottish Government and regeneration agencies south of the border to look at new ways of stimulating house building and delivering mixed tenure affordable housing in the low grant environment. Matthew developed much of the thinking behind the Scottish Futures Trust’s NHT initiative and he has been developing parallel private led initiatives.



A graduate of Cambridge University, Robert moved from farming into the setting up and running of his own, and later, other businesses in the pesticide industry. He then assisted in the setting up of TRI Cap of which he has been Chairman since 2004. Tricap, one of Scotland’s most active business angel syndicates has interests in a number of pharmaceutical businesses including Ryboquin Ltd. A serial Entrepreneur Robert has a number of other business interests including Board membership of the family engineering and property business based in Oxford.